Individuals' experiences in genetic counseling and predictive testing for familial amyotrophic lateral sclerosis

被引:2
|
作者
Steigerwald, Connolly G. [1 ,2 ]
Bertolini, Carina [1 ]
McElhiney, Martin [3 ,4 ]
Bergner, Amanda L. [1 ,5 ]
Harms, Matthew B. [6 ]
Harrington, Elizabeth A. [1 ,6 ]
机构
[1] Columbia Univ, Vagelos Coll Phys & Surg, Genet Counseling Grad Program, New York, NY USA
[2] NYU Grossman Sch Med, Dept Neurol, Div Neurogenet, New York, NY 10016 USA
[3] Columbia Univ, Vagelos Coll Phys & Surg, Dept Psychiat, New York, NY USA
[4] New York State Psychiat Inst & Hosp, New York, NY USA
[5] Columbia Univ, Vagelos Coll Phys & Surg, Dept Genet & Dev, New York, NY USA
[6] Columbia Univ, Vagelos Coll Phys & Surg, Dept Neurol, New York, NY USA
关键词
decision making; genetic counseling; lived experience; predictive genetic testing; psychosocial; HUNTINGTONS-DISEASE; PSYCHOLOGICAL IMPACT; MUTATIONS; PENETRANCE; PROGNOSIS; DECISION; UPDATE; ALS;
D O I
10.1002/jgc4.1890
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
As clinical genetic testing in the amyotrophic lateral sclerosis (ALS) diagnostic setting increases, the identification of at-risk family members has also expanded. No practice guidelines specifically for predictive genetic testing exist, and few studies about the psychological impacts of testing in this subgroup have occurred, limiting the ability to tailor recommendations and counseling in this community. We surveyed asymptomatic individuals at risk for inheriting an ALS-associated gene mutation. The 80-question survey was designed using a combination of validated measures (General Anxiety Disorder; FACToR; Decision Regret Scale) and original items. Ninety participants completed the survey, including those who completed predictive genetic testing (N = 42) and those who did not (N = 48). Gene positive individuals experienced greater negativity, uncertainty, and overall psychological impairment (p = 0.002; p < 0.001; p = 0.001). Individuals who had not undergone testing reported thinking about their risk multiple times per day and experiencing more decisional regret than those who tested (p = 0.006). In terms of decision-making, being prepared for potential clinical drug trials was a more important potential benefit among those who underwent testing (p = 0.026). Participants valuing preparedness for clinical drug trials supports the concept that genetic testing for ALS will increase as research in gene-targeted therapeutics progresses. This study describes factors relevant to the genetic testing decision-making process and adaptation to results from the perspective of at-risk individuals, which can ultimately guide genetic counseling practice in this population.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Experiences with advance care planning in amyotrophic lateral sclerosis: Qualitative longitudinal study with people with amyotrophic lateral sclerosis and their family carers
    Vandenbogaerde, Isabel
    Van den Block, Lieve
    Deliens, Luc
    Carduff, Emma
    van der Heide, Agnes
    De Bleecker, Jan
    De Vleminck, Aline
    PALLIATIVE MEDICINE, 2024, 38 (05) : 572 - 581
  • [32] The lived experience of reconstructing identity in response to genetic risk of frontotemporal degeneration and amyotrophic lateral sclerosis
    Dratch, Laynie
    Owczarzak, Jill
    Mu, Weiyi
    Cousins, Katheryn A. Q.
    Massimo, Lauren
    Grossman, Murray
    Erby, Lori
    JOURNAL OF GENETIC COUNSELING, 2024, 33 (03) : 515 - 527
  • [33] Genetic analysis of CHCHD10 in French familial amyotrophic lateral sclerosis patients
    Teyssou, Elisa
    Chartier, Laura
    Albert, Melanie
    Bouscary, Alexandra
    Antoine, Jean-Christophe
    Camdessanche, Jean-Philippe
    Rotolo, Francesco
    Couratier, Philippe
    Salachas, Francois
    Seilhean, Danielle
    Millecamps, Stephanie
    NEUROBIOLOGY OF AGING, 2016, 42 : 218.e1 - 218.e3
  • [34] Genetic Counseling and Genetic Testing for Familial Hypercholesterolemia
    Tada, Hayato
    Kawashiri, Masa-aki
    Nohara, Atsushi
    Sekiya, Tomoko
    Watanabe, Atsushi
    Takamura, Masayuki
    GENES, 2024, 15 (03)
  • [35] Genetic analysis in Chinese patients with familial or young-onset amyotrophic lateral sclerosis
    Ma, Jing
    Pang, Xiaomin
    Huang, Shan
    Zhang, Jing
    Wang, Juan
    Zhao, Rongjuan
    Chang, Xueli
    Guo, Junhong
    Zhang, Wei
    NEUROLOGICAL SCIENCES, 2022, 43 (04) : 2579 - 2587
  • [36] Genetic analysis of patients with familial and sporadic amyotrophic lateral sclerosis in a Brazilian Research Center
    Chadi, Gerson
    Maximino, Jessica Ruivo
    De Haidar Jorge, Frederico Mennucci
    De Borba, Fabricio Castro
    Gilio, Joyce Meire
    Callegaro, Dagoberto
    Lopes, Camila Galvao
    Dos Santos, Samantha Nakamura
    Sales Rebelo, Gabriela Natania
    AMYOTROPHIC LATERAL SCLEROSIS AND FRONTOTEMPORAL DEGENERATION, 2017, 18 (3-4) : 249 - 255
  • [37] The genotype-phenotype landscape of familial amyotrophic lateral sclerosis in Australia
    McCann, E. P.
    Williams, K. L.
    Fifita, J. A.
    Tarr, I. S.
    O'Connor, J.
    Rowe, D. B.
    Nicholson, G. A.
    Blair, I. P.
    CLINICAL GENETICS, 2017, 92 (03) : 259 - 266
  • [38] SOD1 and cognitive dysfunction in familial amyotrophic lateral sclerosis
    Wicks, P.
    Abrahams, S.
    Papps, B.
    Al-Chalabi, A.
    Shaw, C. E.
    Leigh, P. N.
    Goldstein, L. H.
    JOURNAL OF NEUROLOGY, 2009, 256 (02) : 234 - 241
  • [39] Familial versus sporadic amyotrophic lateral sclerosis-a false dichotomy?
    Talbot, Kevin
    BRAIN, 2011, 134 : 3429 - 3431
  • [40] Screening of OPTN in French familial amyotrophic lateral sclerosis
    Millecamps, Stephanie
    Boillee, Severine
    Chabrol, Elodie
    Camu, William
    Cazeneuve, Cecile
    Salachas, Francois
    Pradat, Pierre-Francois
    Danel-Brunaud, Veronique
    Vandenberghe, Nadia
    Corcia, Philippe
    Le Forestier, Nadine
    Lacomblez, Lucette
    Bruneteau, Gaelic
    Seilhean, Danielle
    Brice, Alexis
    Feingold, Josue
    Meininger, Vincent
    LeGuern, Eric
    NEUROBIOLOGY OF AGING, 2011, 32 (03) : 557.e11 - 557.e13